Breast cancer is classified into four classes (luminal A, luminal B, human epidermal growth factor receptor-2 (HER2), and triple-negative (TN)) according to the expression status of estrogen receptor (ER), progesterone receptor (PR), and HER-2, each with a different general prognosis and appropriate treatment strategy [60,61,62]. This evidence concerns the gene PGR and breast cancer.